Phencyclidine (PCP): How It Affects the Brain and Body

Phencyclidine, better known as PCP or “angel dust,” is a synthetic dissociative drug that was originally developed in the 1950s as an anesthetic but was pulled from human medical use because patients waking up from it experienced severe agitation, hallucinations, and delirium. It went on to become one of the most feared street drugs in America, earning a reputation in the late 1970s as “the most dangerous drug in America” amid sensational media coverage.¹ The reality of PCP is both less cinematic and more scientifically interesting than its pop-culture image suggests, with the drug playing a surprising role in psychiatric research that continues today.

How PCP Works in the Brain

PCP’s primary action is blocking a receptor in the brain called the NMDA receptor, which is involved in learning, memory, and the regulation of excitatory signaling between neurons. Unlike drugs that simply flip a receptor on or off, PCP is a “noncompetitive” blocker, meaning it physically plugs the receptor’s ion channel rather than competing with the receptor’s natural signaling molecule (glutamate) for the same binding site. This is why its effects are so hard for the brain to override on its own.²

But NMDA blockade is only part of the story. PCP also prevents the reuptake of dopamine, serotonin, and norepinephrine, effectively letting those chemical messengers pile up in the spaces between neurons.³ The dopamine piece is particularly important. Research in rats found that a single dose of PCP rapidly increased the packaging of dopamine into synaptic vesicles and boosted activity at a transporter called VMAT-2, an effect that was blocked when a dopamine-receptor antagonist was given first.⁴ This multi-pronged pharmacology is why PCP produces such a wide and unpredictable range of effects: it is not just a hallucinogen, or just a stimulant, or just a sedative. It touches several major neurotransmitter systems at once.

Brain imaging studies in animals have confirmed how widespread this disruption is. In anesthetized rats, a single dose of PCP produced sustained activation across cortical, limbic, thalamic, and striatal regions simultaneously.⁵ Neurochemical measurements in the prefrontal cortex showed a sharp spike in glucose use (up about 70%) alongside a drop in lactate, suggesting a sudden, intense metabolic demand in the brain’s decision-making center.⁶

What Acute Intoxication Actually Looks Like

The popular image of a PCP-intoxicated person as someone with superhuman strength tearing through a wall is mostly myth. Real clinical presentations are less dramatic but still dangerous. A case series of 184 PCP-intoxicated patients treated at a medical center found that the most common sign, by far, was nystagmus: involuntary eye movements. Horizontal nystagmus showed up in about two-thirds of patients, and vertical nystagmus in nearly half. High blood pressure was recorded in roughly half the cases, agitation in about 40%, and amnesia for the episode in about a quarter.⁷

The nystagmus finding is worth dwelling on because it is one of the clinical features that distinguishes PCP intoxication from other drug presentations. Most stimulants do not cause it, and most hallucinogens do not cause it the same way. When emergency physicians see both horizontal and vertical nystagmus in an agitated patient, PCP goes near the top of their differential list. Other common features include a blank, disconnected stare, slurred or garbled speech, numbness in the extremities, and an unusual gait.

At higher doses, the picture shifts from dissociation toward life-threatening toxicity. Sensory isolation and intravenous diazepam (a benzodiazepine) have been the traditional mainstays for managing acute intoxication, especially when seizures develop.⁸ “Sensory isolation” here means placing the patient in a calm, low-stimulation environment, since external stimuli can worsen agitation and psychosis. Antipsychotic medications are sometimes used, though the evidence for their effectiveness in acute PCP crises is debated among toxicologists.

Serious Medical Complications

Beyond the psychiatric effects, PCP can cause a cascade of physical problems that are dangerous in their own right. One of the most concerning is rhabdomyolysis, a condition where muscle tissue breaks down and floods the bloodstream with proteins that can clog the kidneys. In a review of 1,000 PCP-intoxicated patients, rhabdomyolysis occurred in about 2.5% of cases. Of those 25 patients, 40% went on to develop acute kidney failure, and another seven had milder kidney damage. Fever, rapid heart rate, and high blood pressure were common in this subgroup.⁹

Rhabdomyolysis from PCP is thought to result from a combination of extreme muscle tension (sometimes from prolonged agitation or seizures), elevated body temperature, and direct toxic effects on muscle cells. It is one of the main reasons PCP intoxication can be fatal even in young, otherwise healthy people. The kidneys simply cannot handle the flood of myoglobin released from dying muscle tissue.

Why PCP Lingers in the Body

One of PCP’s stranger properties is how long it sticks around. The drug has an unusually strong affinity for fat tissue. In rat studies, adipose-to-plasma ratios ranged from roughly 30 to over 100, meaning fat tissue held concentrations dozens of times higher than what was circulating in the blood.¹⁰ Brain-to-plasma ratios were also high, between about 6 and 9. These numbers explain several clinical puzzles.

First, the drug was detectable in brain and fat tissue long after it had disappeared from the blood. This means standard blood tests can miss PCP in a person who is still under its influence. Second, repeated doses cause the drug to accumulate in fat stores in a way that builds over time. Third, and most troublingly, situations that mobilize fat reserves, such as starvation, rapid weight loss, or severe stress, could theoretically release stored PCP back into the bloodstream.¹¹ Separate distribution studies confirmed that PCP remained in brain tissue long after it was no longer detectable in blood, consistent with the delayed and prolonged symptoms clinicians see at the bedside.¹²

Because PCP is a weak base, its elimination can be influenced by urine pH. In an acidic environment, PCP becomes ionized and cannot be reabsorbed back into the body from the kidneys, so it gets flushed out more quickly. This led to a treatment strategy of acidifying the urine with ammonium chloride, sometimes combined with forced diuresis, to speed up clearance.¹³ Continuous gastric suctioning was also proposed as a way to exploit the same ion-trapping principle in the stomach. In practice, aggressive urine acidification has fallen somewhat out of favor because it carries its own risks, particularly in patients who already have rhabdomyolysis and compromised kidneys. The approach highlights how unusual PCP’s pharmacology is: most drugs of abuse do not prompt doctors to consider manipulating body chemistry just to get them out faster.

Long-Term Brain Effects

Animal research has shown that the damage from PCP is not limited to acute intoxication. In a landmark primate study, monkeys given PCP twice daily for two weeks showed lasting deficits on tasks that depend on the prefrontal cortex, the brain region responsible for planning, working memory, and impulse control. These cognitive problems persisted after the drug was stopped, and so did the underlying biochemical change: a reduction in both baseline and stimulated dopamine activity in the dorsolateral prefrontal cortex. The atypical antipsychotic clozapine improved the behavioral deficits, suggesting the damage was partially reversible at the functional level.¹⁴

At the cellular level, moderate-to-high doses of NMDA receptor blockers including PCP cause a distinctive injury pattern first identified by researcher John Olney: vacuoles (tiny fluid-filled bubbles) form inside neurons of the retrosplenial cortex and posterior cingulate gyrus. After short-term exposure, these lesions can reverse. But with prolonged dosing, the vacuolization progresses to irreversible neuronal death.¹⁵ This is a sobering finding because it suggests there may be a window during early use where the brain can recover, but a point of no return with chronic exposure.

The Schizophrenia Connection

Perhaps the most scientifically significant fact about PCP is its relationship to schizophrenia. Many drugs cause hallucinations, but PCP is unusual in that it reproduces not just the hallucinations and delusions (positive symptoms) but also the social withdrawal, emotional flatness (negative symptoms), and the cognitive deficits that characterize schizophrenia. Chronic PCP users have been misdiagnosed as schizophrenic, and giving PCP to people who already have stabilized schizophrenia worsens their symptoms.¹⁶

This observation reshaped how researchers think about the biology of schizophrenia. Before PCP, the dominant theory was that schizophrenia resulted primarily from too much dopamine activity. PCP’s ability to mimic schizophrenia through NMDA receptor blockade pointed to glutamate signaling as another critical piece of the puzzle. This “glutamate hypothesis” has driven decades of research and drug development aimed at correcting glutamate imbalances rather than simply blocking dopamine. PCP and its chemical cousin ketamine remain among the most widely used tools for modeling schizophrenia-like states in laboratory animals, precisely because no other drug mimics the full symptom profile as convincingly.

False Positives on Drug Tests

If you have never used PCP but tested positive for it on a urine drug screen, you are not alone, and you are not necessarily the victim of a lab error. Standard immunoassay urine tests for PCP are notorious for cross-reacting with structurally unrelated medications. A study that specifically investigated false-positive PCP screens found that tramadol, dextromethorphan (a common cough suppressant), alprazolam, clonazepam, and carvedilol (a blood pressure medication) were all significantly more common among patients who tested falsely positive for PCP than among those with true negatives.¹⁷ Diphenhydramine (the active ingredient in Benadryl) also trended higher in the false-positive group, though the association did not reach statistical significance.

Antidepressants in the SNRI class are another common culprit. Case reports have documented false-positive PCP results with venlafaxine (Effexor), and at least one report has linked the same problem to desvenlafaxine (Pristiq), which is the active breakdown product of venlafaxine.¹⁸ The practical takeaway: an initial positive PCP result on a standard urine screen should always be confirmed by a more specific method, such as gas chromatography-mass spectrometry, before any clinical or legal conclusions are drawn. This is especially important in settings like emergency rooms, pain management clinics, and court-ordered drug testing, where a false positive can have serious consequences.

Designer Analogues and the PCP Family

PCP belongs to a chemical family called arylcyclohexylamines, which also includes ketamine. Over the decades, chemists, both legitimate researchers and illicit manufacturers, have produced numerous structural variations. Some of these have surfaced as “designer drugs” or “research chemicals” sold online. Pharmacological screening of several of these analogues found that methoxetamine (a ketamine derivative) and the 3-methoxy and 4-methoxy analogues of PCP all bound strongly to the NMDA receptor’s PCP site, confirming they work through the same primary mechanism as the parent drug. The PCP analogues also showed significant affinity for the serotonin transporter and for sigma receptors, suggesting their subjective effects could differ from PCP in unpredictable ways.¹⁹

Other structural modifications have produced compounds that barely touch the NMDA receptor at all but hit different targets entirely. One PCP analogue called BTCP, for instance, turned out to be a potent dopamine reuptake inhibitor with low affinity for the PCP binding site, making its behavioral profile more cocaine-like than PCP-like.²⁰ Rigid structural analogues of PCP have been synthesized that selectively bind sigma receptors over the PCP site by ratios of up to 368 to 1.²¹ These compounds are more useful as research tools for studying specific receptor systems than as recreational drugs, but they illustrate how small structural changes to the PCP molecule can radically alter which brain systems it affects. For anyone encountering a “new” dissociative on the unregulated market, the implication is clear: predicting what a novel arylcyclohexylamine will do based on its similarity to PCP is a gamble.

Hidden Dangers in How PCP Is Used

Street PCP is almost always smoked, typically by dipping a cigarette or cannabis joint into liquid PCP or dusting plant material with PCP powder. This route of administration introduces a hazard that has nothing to do with PCP itself: the contaminants produced during its illicit synthesis. The major impurity in illegally manufactured PCP is a compound called PCC (piperidinocyclohexanecarbonitrile). When researchers analyzed what happens to PCC during smoking, they found that roughly half of it survived intact into the mainstream smoke, but about 58% of it broke down to release hydrogen cyanide and a cyclohexene byproduct.²²

Hydrogen cyanide is acutely toxic. While the amount generated from a single hit of a PCP-laced cigarette may not be immediately lethal, repeated exposure is a genuine concern that users are almost certainly unaware of. This cyanide exposure does not appear in standard toxicology panels and would not be tested for in a typical emergency room visit for PCP intoxication. It represents one of the more under-discussed risks of PCP use: you are not just inhaling PCP, you are inhaling whatever byproducts its sloppy synthesis left behind, and some of those byproducts turn into poison when burned.

PCP’s Complicated Legacy in Medicine and Science

PCP was described as the first non-natural, entirely synthetic illicit drug of abuse, a distinction that reflects its unusual trajectory from operating room to street corner.²³ The discovery in 1983 that PCP and ketamine share the property of NMDA receptor antagonism was a turning point not just for understanding these drugs but for neuroscience broadly.²⁴ That single mechanistic insight connected anesthesia, psychosis, addiction, and ultimately the development of ketamine as a rapidly acting antidepressant into a single pharmacological thread. It is difficult to overstate how much of modern glutamate pharmacology grew out of studying what PCP does to the brain.

The media panic of the late 1970s and early 1980s painted PCP users as uniformly violent, impervious to pain, and capable of extraordinary feats of strength. While PCP intoxication can involve agitation, combativeness, and reduced sensitivity to pain, the clinical literature makes clear that these are not universal features. In the case series described earlier, agitation was recorded in fewer than 40% of patients. The “superman” narrative became a self-reinforcing cycle: police and emergency responders expected extreme behavior, and confirmation bias ensured that the most dramatic cases dominated training materials and news coverage. Meanwhile, the more typical PCP patient, disoriented, nystagmic, and hypertensive but not rampaging, received less attention.

PCP use has never disappeared entirely, though it remains far less common than drugs like methamphetamine or fentanyl. It persists in certain regional markets, particularly in parts of the northeastern and mid-Atlantic United States. Its chemical descendants, including ketamine and the growing family of designer dissociatives, carry forward its pharmacological DNA while often lacking the same stigma. Understanding PCP remains relevant not just for toxicologists and emergency physicians, but for anyone trying to make sense of the broader dissociative drug landscape and the neuroscience it helped build.